As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
The hemolysis assay is used to determine the hemolytic effect of a test compound.
Hemolytic activity is a requirement to be tested for any blood contacting medical device. The test is based on erythrocyte lysis induced by contact, leachables, toxins, metal ions, surface charge or any other cause of erythrocyte lysis. The current description is based on direct contact of biomaterial and an erythrocyte suspension. The method is based on release of hemoglobin, which can be measured spectrophotometrically. This method is suited to evaluate the hemocompatibility of biomaterials and medical devices according to the international standard ISO 10993-4:2002.
The Hemolysis test is designed to determine the hemolytic properties of a medical device/material. This test is performed on medical devices/materials that have direct or indirect blood contact.
Evaluate your small molecule, biologic, or formulation excipients for its potential to lyse red blood cells
Personalized experimental design to ensure the most relevant data is obtained with the options to examine all relevant in vivo pharmacologically relevant blood from appropriate species
All assays are performed with high-quality reagents and strict controls by experienced immunologists
Either a minimum of 300 µL of test compound at 10 mM in DMSO, or 5 mg of powder
Molecular mass (exact mass) of the test compound and its salt form
MSDS and handling and storage information, e.g., light sensitive, store at -20°C, etc.
Percent of hemolysis in each sample
Rate of hemolysis, if applicable
Test compound dissolved in DMSO applied to a suspension of red blood cells in isotonic buffer or plasma. The final dosing concentration is typically 10 uM or the clinical Cmax
A suspension of red blood cells from a species specified by the customer
The positive control: red blood cells treated with 0.1% SDS (sodium dodecyl sulfate) to produce 100% hemolysis
The negative control: red blood cells treated with DMSO
Prepare three separate test tubes (N=3) containing red blood cells dosed with the test compound dissolved in DMSO
Incubated at 37°C in a water bath with mild agitation
Sample each replicate at 0, 5, 15, 30, 60, 120 and 180 minutes
Centrifuge each sample
Measure the absorbance of the supernatant from each sample using a UV/Vis spectrometer
Calculate percent hemolysis at each sampling time point
Hemolysis can be determined from between 10 and 100% with a typical precision (N=3) of 10%
Positive and negative controls run with each compound
The customer may select:
either the basic, standard or custom report format
the species of blood donor plasma or isotonic buffer
The customer can request:
additional replicates
the use of a control buffer in which the stability of the test compound is measured
the concentration of the test compound